Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats

por Hallakou‐Bozec, Sophie, Kergoat, Micheline, Moller, David E., Bolze, Sébastien
Publicado 2020

Comment on: Butler et al. Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Gluca...

por Heine, Robert J., Fu, Haoda, Kendall, David M., Moller, David E.
Publicado 2013

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action

por Hallakou-Bozec, Sophie, Kergoat, Micheline, Fouqueray, Pascale, Bolze, Sébastien, Moller, David E.
Publicado 2021

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes

por Hallakou‐Bozec, Sophie, Vial, Guillaume, Kergoat, Micheline, Fouqueray, Pascale, Bolze, Sébastien, Borel, Anne‐Laure, Fontaine, Eric, Moller, David E.
Publicado 2020

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin

por Theurey, Pierre, Vial, Guillaume, Fontaine, Eric, Monternier, Pierre‐Axel, Fouqueray, Pascale, Bolze, Sébastien, Moller, David E., Hallakou‐Bozec, Sophie
Publicado 2022

Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study

por Fouqueray, Pascale, Bolze, Sebastien, Dubourg, Julie, Hallakou-Bozec, Sophie, Theurey, Pierre, Grouin, Jean-Marie, Chevalier, Clémence, Gluais-Dagorn, Pascale, Moller, David E., Cusi, Kenneth
Publicado 2021

Therapeutic potential of deuterium‐stabilized (R)‐pioglitazone—PXL065—for X‐linked adrenoleukodystrophy

por Monternier, Pierre‐Axel, Singh, Jaspreet, Parasar, Parveen, Theurey, Pierre, DeWitt, Sheila, Jacques, Vincent, Klett, Eric, Kaur, Navtej, Nagaraja, Tavarekere N., Moller, David E., Hallakou‐Bozec, Sophie
Publicado 2022

Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis

por Gluais‐Dagorn, Pascale, Foretz, Marc, Steinberg, Gregory R., Batchuluun, Battsetseg, Zawistowska‐Deniziak, Anna, Lambooij, Joost M., Guigas, Bruno, Carling, David, Monternier, Pierre‐Axel, Moller, David E., Bolze, Sebastien, Hallakou‐Bozec, Sophie
Publicado 2021

Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:12...

por Kazda, Christof M., Ding, Ying, Kelly, Ronan P., Garhyan, Parag, Shi, Chunxue, Lim, Chay Ngee, Fu, Haoda, Watson, David E., Lewin, Andrew J., Landschulz, William H., Deeg, Mark A., Moller, David E., Hardy, Thomas A.
Publicado 2017

Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319

por Kharitonenkov, Alexei, Beals, John M., Micanovic, Radmila, Strifler, Beth A., Rathnachalam, Radhakrishnan, Wroblewski, Victor J., Li, Shun, Koester, Anja, Ford, Amy M., Coskun, Tamer, Dunbar, James D., Cheng, Christine C., Frye, Christopher C., Bumol, Thomas F., Moller, David E.
Publicado 2013